Kidney Res Clin Pract > Volume 31(3); 2012 > Article |
|
Factors that were combined or not combined with the patient are expressed as + and −, respectively. Six patients (ID 1-6) were previously described [7].
Six patients (ID 1-6) were previously described [7].
ID |
Contrast-enhanced CT |
Bone scan (d)⁎ | MRI (d)⁎ | |
---|---|---|---|---|
CT contrast (d)⁎ | CT delay (h)† | |||
1 | Diffusely enhanced (12) | Patchy high (48) | Diffuse and delayed uptake (12) | Not done |
2 | Patchy low (10) | Patchy high (24) | Patchy (9) | Not done |
3 | Patchy low (5) | Patchy high (24) | Patchy (3) | Not done |
4 | Diffusely enhanced (4) | Patchy high (24) | Patchy (3) | T1, focal patchy (7) |
5 | Diffusely enhanced (11) | Patchy high (24) | Patchy (10) | T1/T2, focal increased intensity (11) |
6 | Diffusely enhanced (6) | Patchy high (24) | Patchy (6) | Not done |
7 | Patchy low (7) | Patchy high (24) | Diffuse and delayed uptake (8) | Not done |
8 | Patchy low (18) | Patchy high (24) | Not done | T1, wedge-shaped low signal (20) |
9 | Patchy low (1) | Patchy high (48) | Patchy (5) | Not done |
10 | Patchy low (1) | Patchy high (24) | Not done | Not done |
11 | Patchy low (4) | Patchy high (4) | Not done | Not done |
12 | Patchy low (4) | Patchy high (24) | Not done | Not done |
13 | Patchy low (8) | Patchy high (24) | Not done | Not done |
14 | Diffusely enhanced (4) | Patchy high (48) | Not done | Not done |
15 | Patchy low (5) | Patchy high (48) | Patchy (4) | Not done |
16 | Patchy low (5) | Patchy high (4) | Patchy (4) | Not done |
17 | Patchy low (5) | Patchy high (24) | Not done | Not done |
The findings of imaging studies are summarized. Six patients (ID 1-6) were previously described [7].
This study (N=17, n=17) |
Ishikawa et al. [1] (N=118, n=118) |
Ohta et al. [12] (N=54, n=72) |
||||
---|---|---|---|---|---|---|
n | Value | n | Value | n | Value | |
Male sex | 17 | 15 (88.2%) | 118 | 112 (94.9%) | 54 | 48 (88.9%) |
Age (y) | 17 | 23.0±6.5 (16–35) | 118 | 22.0±7.6 (10–54) | 54 | 19.3±8.1 (11–46) |
Loin pain | 17 | 12 (70.6%) | N/A | N/A | 60 | 35 (58.3%)⁎ |
Abdominal pain | 17 | 13 (76.5%) | N/A | N/A | 60 | 22 (36.7%)⁎ |
Nausea or vomiting | 17 | 14 (82.4%) | 88 | 84 (95.5%) | 60 | 51 (85.0%)⁎ |
Fever | 17 | 11 (64.7%) | 47 | 38 (80.9%) | 60 | 7 (11.7%)⁎ |
Oliguria | 17 | 6 (35.3%) | 102 | 16 (15.7%) | 60 | 0 (0%)⁎ |
Flu-like symptoms before pain | 17 | 9 (52.9%) | 53 | 25 (47.2%) | N/A | N/A |
Analgesics ingestion before pain | 17 | 7 (41.2%) | 58 | 22 (37.9%) | N/A | N/A |
Type of exercise | ||||||
Track race | 17 | 8 (47.1%) | 118 | 79 (66.9%) | 61 | 36 (59.0%) |
Running | 17 | 3 (17.6%) | 118 | 5 (4.2%) | 61 | 8 (13.1%) |
Soccer | 17 | 1 (5.9%) | 118 | 9 (7.6%) | 61 | 2 (3.3%) |
Others | 17 | 0 (0%) | 118 | 25 (21.2%) | 61 | 15 (24.6%) |
Duration of pain (d) | 17 | 3.5±4.0 (1 –1 6) | 34 | 4.8±3.3 (1 –1 4) | N/A | N/A |
Duration of renal dysfunction (d) | 17 | 10.8±5.0 (2 –2 2) | 87 | 13.1±8.3 (3 –6 0) | N/A | N/A |
Dialysis | 17 | 1 (5.9%) | 118 | 20 (16.9%) | N/A | N/A |
Recurrence | 17 | 0 (0%) | 118 | 20 (16.9%) | 54 | 13 (24.1%) |
Initial serum creatinine (mg/dL) | 17 | 4.64±2.84 (1.3–12.1) | 77 | 4.70±2.90 (1.1–15.0) | N/A | N/A |
Maximal serum creatinine (mg/dL) | 17 | 5.42±3.16 (1.4–12.1) | 109 | 6.00±3.00 (1.2–15.0) | 68 | 5.45±3.33 (1.1–17.7) |
Maximal serum uric acid (mg/dL) | 17 | 9.41±2.91 (6.0–15.8) | N/A | N/A | 59 | 4.40±2.49 (0.4–13.3) |
Serum uric acid after recovery (mg/dL) | 17 | 5.49±2.08 (1.5–7.2) | N/A | N/A | 54 | 0.70±0.25 (0.1–1.4) |
Proportion of renal hypouricemia | 7 | 1 (14.3%) | 96 | 49 (51.0%) | 48 | 48 (100%) |
CT scan of patchy lesions | 17 | 17 (100%) | 50 | 46 (92.0%) | N/A | N/A |
Bone scan of patchy lesions | 10 | 8 (80%) | 20 | 12 (60.0%) | N/A | N/A |
MRI of patchy lesions | 3 | 3 (100%) | N/A | N/A | N/A | N/A |
Clinical Characteristics of Pneumonia Occurred in Hemodialysis Patients2007 September;26(5)